· Published by Health Canada · Official notice
This is duplicated text of a letter from Amgen Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.
May 28, 2012
Dear Healthcare Professional:
Subject: Xgeva® (denosumab) - Risk of severe symptomatic hypocalcemia, including fatal cases
Amgen Canada Inc., in consultation with Health Canada, would like to inform you of new important safety information related to hypocalcemia associated with Xgeva treatment.
Xgeva is indicated in patients with bone metastases from breast cancer, prostate cancer, non-small cell lung cancer, and other solid tumours for reducing the risk of developing skeletal-related events (SREs). Xgeva is not indicated in patients with multiple myeloma. Xgeva is administered as a single 120 mg subcutaneous injection given once every 4 weeks.
Important information for healthcare professionals
The Xgeva Product Monograph is being updated to include new safety information on severe symptomatic hypocalcemia, which can sometimes be fatal.
A copy of this letter is available on the Health Canada Web site. This information is also available on the Amgen Canada Web site.
Further Information
For more information regarding Xgeva, refer to the Xgeva Product Monograph, which can be found on the Amgen Canada Web site or on the Xgeva Canada Web site.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of severe symptomatic hypocalcemia or other serious or unexpected adverse reactions in patients receiving Xgeva (denosumab) should be reported to Amgen Canada Inc. or Health Canada at the following addresses:
Amgen Canada Inc.
6775 Financial Drive, Suite 100
Mississauga, Ontario L5N 0A4
Safety Tel: 1-866-512-6436 or Fax: 1-888-264-3655
Safety e-mail: safetycanada@amgen.com
To correct your mailing address or fax number, contact Amgen Canada Inc.
To report suspected adverse reactions to these or other health products, please contact Health Canada's Canada Vigilance Program toll-free at 1-866-234-2345, or visit the MedEffect™ Canada Web site for information on how to report.
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Sincerely,
original signed by
Clive Ward-Able, MD
Executive Medical Director
AMGEN Canada Inc.